Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$1.83 - $5.52 $3.83 Million - $11.6 Million
-2,093,416 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$5.65 - $14.9 $3.92 Million - $10.3 Million
693,928 Added 49.58%
2,093,416 $12.6 Million
Q3 2021

Nov 15, 2021

BUY
$9.91 - $14.84 $2.74 Million - $4.11 Million
276,955 Added 24.67%
1,399,488 $19.4 Million
Q1 2021

May 14, 2021

BUY
$14.7 - $30.57 $16.5 Million - $34.3 Million
1,122,533 New
1,122,533 $17.3 Million

Others Institutions Holding GRCL

About Gracell Biotechnologies Inc.


  • Ticker GRCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,674,096
  • Description
  • Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...
More about GRCL
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.